{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:16:13Z","timestamp":1789474573375,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ceruvia Lifesciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11916-023-01145-y","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T06:01:37Z","timestamp":1691128897000},"page":"489-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Potential of Psychedelics for the Treatment of\u00a0Episodic\u00a0Migraine"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-0365","authenticated-orcid":false,"given":"Emmanuelle A. D.","family":"Schindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"issue":"2","key":"1145_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1145_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"\u2022\u2022 Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534\u201343. https:\/\/doi.org\/10.1007\/s13311-020-00962-y. First controlled study of a classic psychedelic in any headache disorder.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"1145_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","volume":"47","author":"EA Schindler","year":"2015","unstructured":"Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey. J Psychoactive Drugs. 2015;47(5):372\u201381. https:\/\/doi.org\/10.1080\/02791072.2015.1107664.","journal-title":"J Psychoactive Drugs"},{"issue":"12","key":"1145_CR4","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","volume":"66","author":"RA Sewell","year":"2006","unstructured":"Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920\u20132.","journal-title":"Neurology"},{"issue":"4","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ncl.2019.07.003","volume":"37","author":"A Perez-Munoz","year":"2019","unstructured":"Perez-Munoz A, Buse DC, Andrasik F. Behavioral interventions for migraine. Neurol Clin. 2019;37(4):789\u2013813. https:\/\/doi.org\/10.1016\/j.ncl.2019.07.003.","journal-title":"Neurol Clin"},{"issue":"23","key":"1145_CR6","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2021.7939","volume":"325","author":"JH VanderPluym","year":"2021","unstructured":"VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA, J Am Med Assoc. 2021;325(23):2357\u201369. https:\/\/doi.org\/10.1001\/jama.2021.7939.","journal-title":"JAMA, J Am Med Assoc"},{"issue":"3","key":"1145_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11916-022-01024-y","volume":"26","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Hoffmann J, Akerman S. Devices for episodic migraine: past, present, and future. Curr Pain Headache Rep. 2022;26(3):259\u201365. https:\/\/doi.org\/10.1007\/s11916-022-01024-y.","journal-title":"Curr Pain Headache Rep"},{"issue":"7","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688\u201395. https:\/\/doi.org\/10.1212\/WNL.0000000000001256.","journal-title":"Neurology"},{"issue":"3","key":"1145_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","volume":"48","author":"M Good","year":"2023","unstructured":"Good M, Joel Z, Benway T, Routledge C, Timmermann C, Erritzoe D, et al. Pharmacokinetics of N, N-dimethyltryptamine in humans. Eur J Drug Metab Pharmacokinet. 2023;48(3):311\u201327. https:\/\/doi.org\/10.1007\/s13318-023-00822-y.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295\u2013314. https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00059.x.","journal-title":"CNS Neurosci Ther"},{"key":"1145_CR11","unstructured":"Wold R. Transcutaneous migraine abortive effects of psilocybin mushrooms. Personal communication, 2023."},{"issue":"10","key":"1145_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11916-020-00899-z","volume":"24","author":"D Vekhter","year":"2020","unstructured":"Vekhter D, Robbins MS, Minen M, Buse DC. Efficacy and feasibility of behavioral treatments for migraine, headache, and pain in the acute care setting. Curr Pain Headache Rep. 2020;24(10):66. https:\/\/doi.org\/10.1007\/s11916-020-00899-z.","journal-title":"Curr Pain Headache Rep"},{"key":"1145_CR13","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia: an international journal of headache. 2013;33(9):629\u2013808.\u00a0https:\/\/doi.org\/10.1177\/0333102413485658.","DOI":"10.1177\/0333102413485658"},{"issue":"6","key":"1145_CR14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","volume":"52","author":"E Loder","year":"2012","unstructured":"Loder E, Burch R, Rizzoli P. The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930\u201345. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02185.x.","journal-title":"Headache"},{"issue":"4","key":"1145_CR15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/j.pain.0000000000002778","volume":"164","author":"M Lyes","year":"2023","unstructured":"\u2022 Lyes M, Yang KH, Castellanos J, Furnish T. Microdosing psilocybin for chronic pain: a case series. Pain. 2023;164(4):698\u2013702. https:\/\/doi.org\/10.1097\/j.pain.0000000000002778. Case series on self-administration of psilocybin in chronic pain disorders.","journal-title":"Pain"},{"issue":"4","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1526-4610.2012.02123.x","volume":"52","author":"AM Rapoport","year":"2012","unstructured":"Rapoport AM. What happens to the old headache medicines? Headache. 2012;52(4):701\u20136. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02123.x.","journal-title":"Headache"},{"key":"1145_CR17","doi-asserted-by":"publisher","unstructured":"Koehler PJ, Tfelt-Hansen PC. History of methysergide in migraine. Cephalalgia: an international journal of headache. 2008;28(11):1126\u201335.\u00a0https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01648.x.","DOI":"10.1111\/j.1468-2982.2008.01648.x"},{"issue":"2","key":"1145_CR18","first-page":"720","volume":"276","author":"DB Wainscott","year":"1996","unstructured":"Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL. Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther. 1996;276(2):720\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1145_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61(3):364\u201381. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.017.","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"1145_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2008.07.040","volume":"594","author":"D Cussac","year":"2008","unstructured":"Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, et al. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq\/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008;594(1\u20133):32\u20138. https:\/\/doi.org\/10.1016\/j.ejphar.2008.07.040.","journal-title":"Eur J Pharmacol"},{"issue":"6624","key":"1145_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1126\/science.abn5486","volume":"378","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD, D\u2019Souza DC. The therapeutic potential of psychedelics. Science. 2022;378(6624):1051\u20133. https:\/\/doi.org\/10.1126\/science.abn5486.","journal-title":"Science"},{"issue":"12","key":"1145_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11916-020-00909-0","volume":"24","author":"BM Plato","year":"2020","unstructured":"Plato BM, Whitt M. Interventional procedures in episodic migraine. Curr Pain Headache Rep. 2020;24(12):75. https:\/\/doi.org\/10.1007\/s11916-020-00909-0.","journal-title":"Curr Pain Headache Rep"},{"issue":"11","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434\u201352. https:\/\/doi.org\/10.1177\/0269881110382466.","journal-title":"J Psychopharmacol"},{"key":"1145_CR24","doi-asserted-by":"publisher","unstructured":"Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. clinical pharmacology and therapeutics. 2017;101(2):209\u201319.\u00a0https:\/\/doi.org\/10.1002\/cpt.557.","DOI":"10.1002\/cpt.557"},{"issue":"2","key":"1145_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/13554794.2018.1468469","volume":"24","author":"V Ramachandran","year":"2018","unstructured":"Ramachandran V, Chunharas C, Marcus Z, Furnish T, Lin A. Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase. 2018;24(2):105\u201310. https:\/\/doi.org\/10.1080\/13554794.2018.1468469.","journal-title":"Neurocase"},{"issue":"10","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","volume":"62","author":"EAD Schindler","year":"2022","unstructured":"\u2022\u2022 Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383\u201394. https:\/\/doi.org\/10.1111\/head.14420. First controlled study of psilocybin in cluster headache; uses a regimen informed by patient practices.","journal-title":"Headache"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-023-01145-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:25:56Z","timestamp":1693214756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-023-01145-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s11916-023-01145-y","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"20 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"EADS currently receives research funding from Ceruvia Lifesciences and Wallace Research Foundation and previously received research funding from Heffter Research Institute and Clusterbusters. She serves on the scientific advisory boards for Ceruvia Lifesciences and Clusterbusters and serves as a paid consultant for PureTech Health. She is named inventor on the following patent related to psychedelics in headache disorders: 17\/168,638 (US); 2021709245 (EP); 3,166,785 (CA); and 2022\u2013547896 (JP).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}